The Effects of Systemic Cyclosporine on Ocular Outcomes in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis

Abstract

Purpose: To evaluate the effect of systemic cyclosporine on ocular disease in Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) patients. Methods: For this retrospective, comparative study patients were divided into 2 groups: those who received cyclosporine and those who did not receive cyclosporine. Best-corrected visual acuity (BCVA) and chronic ocular surface complications score (COCS; range, 0 -13) at final follow-up were compared between the two groups. Results: The median age and follow-up period of patients was 29 years (range, 1.5 to 71 years) and 16.8 months (range, 3.67 to 91.58 months), respectively. BCVA, COCS, meibomian gland dysfunction, limbal stem cell deficiency, and the need for mucous membrane grafting and scleral lenses were not significantly different between patients who received systemic cyclosporine as compared to patients who did not receive systemic cyclosporine. Conclusions: In this limited study we could identify no association of cyclosporine with improved ocular function or fewer chronic ocular complications later in their clinical course.